Key result
Pharmacokinetic simulations identified an improved dabigatran regimen requiring five dosing schedules based on renal function to best achieve therapeutic trough plasma levels of 75-150 ng/mL.
Why the study?
Because the relationship between dabigatran dose and plasma concentration is highly variable, pharmacokinetic simulations were needed to evaluate label dosing versus alternative regimens across real-world renal function ranges.
Does a five-schedule renal function-based dosing regimen improve the achievement of therapeutic dabigatran plasma concentrations compared to standard label dosing in adults with atrial fibrillation?
Does a five-schedule renal function-based dosing regimen improve the achievement of therapeutic dabigatran plasma concentrations compared to standard label dosing in adults with atrial fibrillation?
A simulated five-schedule dosing regimen for dabigatran based on renal function better achieves therapeutic plasma concentrations than the standard two-dose label scheme.
Five-schedule renal dosing may better achieve therapeutic dabigatran levels; extends PK modeling but leaves clinical outcomes open.
Dabigatran is the first of four direct-acting oral anticoagulants approved to prevent stroke in adult patients with atrial fibrillation using a fixed two-dose scheme compared with warfarin dosing adjusted to a prothrombin time range associated with optimal risk reduction in stroke and serious bleeding. The pivotal phase III trial found dabigatran, depending on dose, is superior to warfarin in stroke reduction and similar in bleeding risk while also showing dabigatran efficacy and safety correlate with steady-state plasma concentrations. Because the relationship between dabigatran dose and plasma concentration is highly variable, a previously developed population pharmacokinetic model of over 9,000 clinical trial patients was used as a basis for simulations comparing the performance of dosing via the drug label to other proposed doses and regimens. Assessment of dosing regimen performance was based on simulations of trough plasma levels within the therapeutic concentration range of 75-150 ng/mL over a renal function range of 15-250 mL/min creatinine clearance, representing extremes for real-world patients. An improved regimen that best achieves this therapeutic range was identified, requiring five different dosing schedules, corresponding to specified renal function ranges, compared with the two approved in the label. The discussion focuses on how this information could better inform patient outcomes and future dabigatran development.
No takes yet. Share an insight, caveat, or question.
Powell et al. (2023) studied Atrial Fibrillation (n=9,000). Dabigatran dosing regimens based on renal function vs. Two approved doses in the drug label was evaluated on Trough plasma levels within the therapeutic concentration range of 75-150 ng/mL. Pharmacokinetic simulations identified an improved dabigatran regimen requiring five dosing schedules based on renal function to best achieve therapeutic trough plasma levels of 75-150 ng/mL.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: